IRADIMED (IRMD) CEO-linked trusts sell 7,500 company shares in plan trades

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7. Reported sale prices ranged from $94.36 to $96.78 per share, and the filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 5, 2025.

Following these sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, and states that Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($717,208)

Net Sell 7 txns

Insider Susi Roger E.

Role CEO, President, Chairman

Sold 7,500 shs ($717K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,518	$94.36	$143K
Sale	Common Stock	982	$95.58	$94K
Sale	Common Stock	1,357	$95.21	$129K
Sale	Common Stock	3,074	$96.24	$296K
Sale	Common Stock	569	$96.78	$55K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,218,482 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $94.54 to $95.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $95.61 to $96.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $96.61 to $97.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $94.15 to $95.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $95.17 to $95.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 7,500 shares Lowest reported sale price: $94.36 per share Highest reported sale price: $96.78 per share +3 more

6 metrics

Shares sold 7,500 shares Open-market sales on April 6–7, 2026

Lowest reported sale price $94.36 per share Common stock sale by trust

Highest reported sale price $96.78 per share Common stock sale by trust

Shares held by Phillip Susi 2008 Dynasty Trust 2,217,500 shares Indirect holding after reported sales

Shares held by Roger E. Susi Revocable Trust 162,950 shares Indirect holding as of April 6, 2026

Shares held by Matthew Susi 2008 Dynasty Trust 2,062,500 shares Indirect holding as of April 6, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Section 16, Dynasty Trust, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Section 16 regulatory

"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Dynasty Trust financial

"By Phillip Susi 2008 Dynasty Trust"

Revocable Trust financial

"By Roger E. Susi Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Form 4 Insider Transactions: What Each Field Means →

04/07/2026 - 03:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last)

(First)

(Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO

FLORIDA

32826

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/06/2026		S⁽¹⁾		1,357	D	$95.21⁽²⁾	2,223,643	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/06/2026		S⁽¹⁾		3,074	D	$96.24⁽³⁾	2,220,569	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/06/2026		S⁽¹⁾		569	D	$96.78⁽⁴⁾	2,220,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/07/2026		S⁽¹⁾		1,518	D	$94.36⁽⁵⁾	2,218,482	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	04/07/2026		S⁽¹⁾		982	D	$95.58⁽⁶⁾	2,217,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500⁽⁷⁾	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $94.54 to $95.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $95.61 to $96.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $96.61 to $97.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $94.15 to $95.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $95.17 to $95.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Roger E. Susi	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did IRADIMED (IRMD) report for Roger E. Susi?

IRADIMED reported that a trust associated with CEO Roger E. Susi sold 7,500 common shares. The Phillip Susi 2008 Dynasty Trust executed open-market sales on April 6–7 at reported prices between $94.36 and $96.78 per share, under a pre-established Rule 10b5-1 trading plan.

How many IRADIMED (IRMD) shares were sold and at what prices?

The filing shows total open-market sales of 7,500 IRADIMED common shares. Reported weighted-average prices for the individual trades ranged from $94.36 to $96.78 per share across April 6–7, with several transactions executed in multiple trades within narrower intraday price ranges.

Who actually holds the IRADIMED (IRMD) shares involved in these transactions?

The sold shares were held by the Phillip Susi 2008 Dynasty Trust, an entity associated with Roger E. Susi. After the sales, that trust holds 2,217,500 shares. Additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on November 5, 2025, indicating that the transactions were pre-arranged rather than decided at the time of execution.

How many IRADIMED (IRMD) shares remain held after the reported sales?

After the open-market sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 IRADIMED shares. The filing also reports 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust as additional indirect holdings.

Does Roger E. Susi claim full beneficial ownership of the reported IRADIMED (IRMD) shares?

No. A footnote explains that Susi disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest. The filing clarifies that including these trust-held shares should not be considered an admission of full beneficial ownership under Section 16.